Amgen notches positive PhIII results for top cancer drug
John Carroll Once again, Amgen's R&D chief Sean Harper has Roger Perlmutter to thank for a positive late-stage outcome on one of the Big Biotech's top cancer prospects. FierceBiotech News
View ArticleJapanese biotech Prism snags $15M C round for cancer, fibrosis studies
John Carroll FierceBiotech News
View ArticleVerastem Cancer Treatment Gets European Incentives
barbara.lempert NEW YORK (AP) — Cancer drug developer Verastem Inc. said Thursday that its most advanced experimental treatment was awarded orphan drug status in the European Union. The decision by the...
View ArticleHerceptin Gets OK in Japan for Postoperative Adjuvant Chemotherapy in Breast...
barbara.lempert Anti-Cancer Agent, Herceptin® Obtained Approval for Dosage and Administration for Postoperative Adjuvant Chemotherapy in Breast Cancer June 14, 2013 (Tokyo) – Chugai Pharmaceutical Co.,...
View ArticleTarceva OK’d in Japan for Lung Cancer
barbara.lempert Anti-Cancer Agent “Tarceva®,” Obtained Approval for Additional Indication (First Line Therapy) of Non-Small Cell Lung Cancer with EGFR Mutations June 14, 2013 (Tokyo) – Chugai...
View ArticleJ&J snags another promising prostate cancer drug in $1B Aragon buyout
John Carroll The deal gives J&J complete control over a combo approach with blockbuster potential that could help further improve the rapidly changing standard of care in prostate cancer....
View ArticleSanofi reboots research of ovarian cancer in academic collaboration
Ryan McBride After a series of setbacks in its hunt for ovarian-cancer drugs, Sanofi has struck a three-year partnership deal with the Curie Institute in France that brings scientists back to the...
View ArticleNEA’s Mott, Kleiner Perkins pump $20M into cancer drug upstart
John Carroll David Mott at New Enterprise Associates has put together a $ 20 million round to back 3-V Biosciences, an upstart biotech with deep roots in Switzerland's scientific community and an...
View ArticleBayer beefs up cancer drug pipeline with $520M armed antibody deal with...
John Carroll Seattle Genetics, which has a who's who in oncology drug development signed on as ADC collaborators, gets $ 20 million of that upfront with the rest in milestones. FierceBiotech News
View ArticleMedivation, Astellas Start Phase II Breast Cancer Study
barbara.lempert Medivation and Astellas Initiate Phase 2 Study of Enzalutamide in Breast Cancer Patients SAN FRANCISCO, CA and TOKYO — (Marketwired) — 06/26/13 — Medivation, Inc. (NASDAQ: MDVN) and...
View ArticleGenentech eyes ‘breakthrough’ cancer immunotherapies in pact with U.K. biotech
Ryan McBride With unleashing the immune system on cancers all the rage in pharma research, Genentech has sealed a deal with the U.K. drug developer Immunocore to tap its T cell receptor technology for...
View ArticleVerastem Initiates Phase 1 Clinical Trial of VS-4718 in Patients with...
barbara.lempert –VS-4718 is the Second Cancer Stem Cell Inhibitor to Enter Clinical Development– CAMBRIDGE, Mass.–(BUSINESS WIRE)–Verastem, Inc., (NASDAQ: VSTM) focused on discovering and developing...
View ArticleRoche bids for broad use of HPV test to screen for cervical cancer
Tracy Staton Roche is aiming to make its human papillomavirus test a first-line diagnostic for cervical cancer, with a new FDA application for the Cobas HPV as a substitute for Pap tests. FiercePharma...
View ArticleNanoparticles, ‘pH phoresis’ could improve cancer drug delivery
barbara.lempert WEST LAFAYETTE, Ind. — Researchers have developed a concept to potentially improve delivery of drugs for cancer treatment using nanoparticles that concentrate and expand in the presence...
View ArticleGlaxoSmithKline teams with Immunocore on next-gen cancer immunotherapies
John Carroll It took more than a decade for the executive team at Immunocore to achieve their first Big Pharma partnership for their new approach to developing revved up immunotherapies for cancer. But...
View ArticleForma enlists expert partners to create a portfolio of virtual cancer biotechs
John Carroll Forma Therapeutics has enlisted some expert assistance through Cancer Research UK's extensive scientific network to drum up a slate of new cancer drug programs in the field of protein...
View ArticleMylan’s $1.6B Agila buyout hits snag in India amid cancer drug worries
Tracy Staton Mylan agreed to pay $ 1.6 billion for Agila Specialties, the injectables unit of Strides Arcolab. But Indian regulators are said to be skeptical of the deal, worried about foreign...
View ArticleNew EU-funded consortium to develop fully personalized cancer vaccines for...
barbara.lempert • Glioma Actively Personalized Vaccine Consortium (GAPVAC): 14 organizations in Europe and the US join forces to develop a completely novel approach to fight cancer •...
View ArticleJ&J files FDA app for fast-moving cancer candidate ibrutinib
Tracy Staton The closely watched cancer treatment ibrutinib, winner of three "breakthrough" designations from the FDA, is now ready for the agency's review. FiercePharma News
View ArticleArray inks $434M licensing deal on cancer drug program
John Carroll A New York-based biotech startup funded by Aisling Capital has stepped up to partner with Array BioPharma on a preclinical cancer program. Loxo Oncology will fund the preclinical work...
View Article
